IMPORTANCE Mutations of the glucocerebrosidase gene, GBA1 (OMIM 606463), are the most important risk factor for Parkinson disease (PD). In vitro and in vivo studies have reported that ambroxol increases β-glucocerebrosidase (GCase) enzyme activity and reduces α-synuclein levels. These observations support a potential role for ambroxol therapy in modifying a relevant pathogenetic pathway in PD.

OBJECTIVE To assess safety, tolerability, cerebrospinal fluid (CSF) penetration, and target engagement of ambroxol therapy with GCase in patients with PD with and without GBA1 mutations.

INTERVENTIONS An escalating dose of oral ambroxol to 1.26 g per day.

DESIGN, SETTING, AND PARTICIPANTS This single-center open-label noncontrolled clinical trial was conducted between January 11, 2017, and April 25, 2018, at the Leonard Wolfson Experimental Neuroscience Centre, a dedicated clinical research facility and part of the University College London Queen Square Institute of Neurology in London, United Kingdom. Participants were recruited from established databases at the Royal Free London Hospital and National Hospital for Neurology and Neurosurgery in London. Twenty-four patients with moderate PD were evaluated for eligibility, and 23 entered the study. Of those, 18 patients completed the study; 1 patient was excluded (failed lumbar puncture), and 4 patients withdrew (predominantly lumbar puncture–related complications). All data analyses were performed from November 1 to December 14, 2018.

MAIN OUTCOMES AND MEASURES Primary outcomes at 186 days were the detection of ambroxol in the CSF and a change in CSF GCase activity.

RESULTS Of the 18 participants (15 men [83.3%]; mean [SD] age, 60.2 [9.7] years) who completed the study, 17 (8 with GBA1 mutations and 9 without GBA1 mutations) were included in the primary analysis. Between days 0 and 186, a 156-ng/mL increase in the level of ambroxol in CSF (lower 95% confidence limit, 129 ng/mL; \( P < .001 \)) was observed. The CSF GCase activity decreased by 19% (0.059 nmol/mL per hour; 95% CI, –0.115 to –0.002; \( P = .04 \)). The ambroxol therapy was well tolerated, with no serious adverse events. An increase of 50 pg/mL (13%) in the CSF α-synuclein concentration (95% CI, 14–87; \( P = .01 \)) and an increase of 88 ng/mmol (35%) in the CSF GCase protein levels (95% CI, 40–137; \( P = .002 \)) were observed. Mean (SD) scores on part 3 of the Movement Disorders Society Unified Parkinson Disease Rating Scale decreased (ie, improved) by 6.8 (7.1) points (95% CI, –10.4 to –3.1; \( P = .001 \)). These changes were observed in patients with and without GBA1 mutations.

CONCLUSIONS AND RELEVANCE The study results suggest that ambroxol therapy was safe and well tolerated, CSF penetration and target engagement of ambroxol were achieved, and CSF α-synuclein levels were increased. Placebo-controlled clinical trials are needed to examine whether ambroxol therapy is associated with changes in the natural progression of PD.

TRIAL REGISTRATION ClinicalTrials.gov identifier: NCT02941822; EudraCT identifier: 2015-002571-24

Published online January 13, 2020.
Mutations in the glucocerebrosidase gene, GBA1 (OMIM 606463), cause the autosomal recessive lysosomal storage disorder, Gaucher disease. These mutations are the most important genetic risk factor for Parkinson disease (PD), exhibiting penetrance of 10% to 30%. They are present in 5% to 15% of Caucasian patients with PD, 25% of Ashkenazi Jewish patients with PD, and 1% of individuals without PD.

In GBA1 cell and animal models, an increased α-synuclein accumulation and a reciprocal relationship between α-synuclein levels and β-glucocerebrosidase (GCase) enzyme activity have been reported. Although GCase activity is reduced in the brains of patients with PD with and without GBA1 mutations, it is lower in those with the mutations. Reduced GCase activity in the brain is associated with increased levels of α-synuclein. In addition, GCase activity is decreased in the cerebrospinal fluid (CSF) of patients with PD with and without GBA1 mutations compared with controls. Upregulation of brain cytosolic/lysosomal GCase activity may reduce α-synuclein levels, mediating a neuroprotective effect in patients with PD both with and without GBA1 mutations.

Ambroxol therapy has been safely used as a cough linctus since the 1970s (summary of product characteristics in eMethods 1 in Supplement 2). Its principal adverse effects are gastrointestinal disturbance and a small risk of anaphylaxis. A high-throughput compound evaluation indicated that ambroxol delivered a pH-dependent increase in GCase activity.

Ambroxol administration has also been reported to increase GCase activity and reduce α-synuclein levels in vitro and in vivo. Ambroxol is an inhibitory chaperone that mobilizes the sequestered mutant GCase from the endoplasmic reticulum by binding to and inhibiting the enzyme active site, inducing conformational change and facilitating transportation to the lysosome. In the acidic lysosome, ambroxol is eluted, allowing normal catalysis to resume and restoring lysosomal function.

Ambroxol may modulate α-synuclein levels through several mechanisms. The GCase may have a direct role in α-synuclein protein disposal, and ambroxol has been shown to upregulate GCase expression through the transcription factor EB pathway and stimulation of lysosomal exocytosis. Alternatively, GBA1 mutations may interrupt physiologic posttranslational folding, preventing transportation of the enzyme to the lysosome. This interruption appears to result in sequestration in the endoplasmic reticulum and an unfolded protein response that may induce α-synuclein aggregation. Evidence also suggests that ambroxol corrects posttranslational folding, mitigating unfolded protein response.

We investigated the biological changes associated with ambroxol therapy in human participants and its consequences on the biochemical and clinical markers of PD. The primary end points were safety and tolerability of ambroxol therapy, central nervous system penetration, and change in CSF GCase activity between baseline and 186 days.

Key Points

Question Does ambroxol cross the blood-brain barrier, and what are the biochemical changes associated with ambroxol therapy in patients with Parkinson disease with and without glucocerebrosidase gene mutations?

Findings In this open-label clinical trial of 17 patients with Parkinson disease, ambroxol crossed the blood-brain barrier and bound to the β-glucocerebrosidase enzyme, and it increased β-glucocerebrosidase enzyme protein levels and cerebrospinal fluid α-synuclein levels in patients both with and without glucocerebrosidase gene mutations.

Meaning Ambroxol therapy has potential for study as a neuroprotective compound for the treatment of patients with Parkinson disease both with and without glucocerebrosidase gene mutations.

Methods

Study Design and Participants

We performed a single-center open-label noncontrolled clinical trial of oral ambroxol therapy (escalating dose to 1.26 g per day [420 mg 3 times per day]) in patients with PD of moderate severity. The clinical trial was conducted at the Leonard Wolfson Experimental Neuroscience Centre, a dedicated clinical research facility at the University College London Queen Square Institute of Neurology from January 11, 2017, to April 25, 2018. A clinical trial steering committee provided clinical oversight. Statistical support was provided by the Peninsula Clinical Trials Unit of the University of Plymouth in the United Kingdom. The study was approved by the Institutional Joint Research Office of University College London, the UK Medicines and Healthcare products Regulatory Agency, and the London-Bloomsbury Research Ethics Committee. Written informed consent was obtained from all participants before study-related procedures were initiated. The study was conducted in accordance with the ethical principles of the Declaration of Helsinki and the Guideline for Good Clinical Practice. The trial protocol is available in Supplement 1, and a detailed summary of study visits is available in eTable 1 in Supplement 2.

Patients were recruited from the established research databases of the National Hospital for Neurology and Neurosurgery and the Royal Free London Hospital. Eligible participants were aged 40 to 80 years, had idiopathic PD as defined by Queen Square Brain Bank criteria, were judged able to self-administer the clinical trial drug, and were at stage 3 or less on the Hoehn and Yahr Scale, which classifies the progression of PD symptoms in 5 stages (stage 1 indicates unilateral involvement only, and stage 5 indicates wheelchair-bound or bedridden unless aided). A portion of participants were preselected on the basis of their known GBA1 mutation–carrier status. Key exclusion criteria included the use of an interventional medicinal product within the last 30 days or exposure to 3 or more interventional medicinal products within the last 12 months. All participants underwent confirmatory sequencing of exons 1 to 11 of the GBA1 gene. A full list of exclusion and reasons is available in eTable 2.
The 186-day exposure period comprised 28 days of dose escalation, with each dose administered 3 times per day as follows: 60 mg (days 1-7), 120 mg (days 8-14), 180 mg (days 15-21), and 300 mg (days 22-28). This exposure period was followed by 158 days of administration of ambroxol at 1.26 g per day (420 mg 3 times per day). Patients were issued ambroxol therapy in 2 batches, 1 at baseline and 1 at 93 days. Ambroxol tablets were donated by PRO.MED.CSPrahaas. (Prague, Czech Republic).

All patients were taking dopaminergic therapy, and levodopa dosage equivalents have been included in Table 1. Participants attended each visit in an off-medication state, defined as more than 8 hours (overnight) of withdrawal of levodopa or more than 24 hours of withdrawal of levodopa for those taking modified-release dopamine agonists.

Assessments were performed between 8 AM and 9 AM by a single assessor (S.M.). Measurement instruments included (1) the Movement Disorder Society Unified Parkinson Disease Rating Scale (MDS-UPDRS; score range, 0-272, with 0 indicating no disability and 272 indicating total disability), which was administered on days 0, 93, 186, and 279; (2) the Montreal Cognitive Assessment (MoCA; score range, 0-30, with ≥26 indicating normal cognitive function), which was administered on days 0 and 186; (3) the Non-Motor Symptoms Scale (NMSS; score range, 0-360, with 0 indicating no severity and frequency of symptoms and 360 indicating high severity and frequency of symptoms), which was administered on days 0 and 186; and (4) the Non-Motor Symptoms Questionnaire (NMSQuest; 30 items evaluating the presence of nonmotor symptoms, with 0 indicating no presence of symptoms and 30 indicating maximum presence of symptoms), which was administered on days 0 and 186.

Empty ambroxol blister packs were collected at 93 and 186 days to assess participant adherence to treatment. All adverse events (AEs), biochemical results (eTable 2 in Supplement 2), and measurements of blood pressure, heart rate, and weight were recorded.

Outcomes
The primary outcomes, all assessed at 186 days, were change in CSF ambroxol levels and change in CSF GCase activity. The predefined secondary outcomes, all assessed at 186 days, were the safety and tolerability of ambroxol in the study population (measured by the frequency and severity of AEs and abnormal findings on clinical examinations, blood tests, or electrocardiograms), the change in blood leucocyte GCase activity, the change in CSF GCase protein levels, the CSF total glucosylceramide levels, the CSF and serum α-synuclein levels, and the CSF and serum tau levels. We also recorded the results of the MoCA, NMSS, and NMSQuest assessments that were conducted at baseline and 186 days.

Sample Collection, Assays, and Statistics
Cerebrospinal fluid was collected before 10 AM from participants after they had fasted overnight. Samples were frozen at -80 °C within 60 minutes of collection in the case of CSF and within 90 minutes of collection in the case of leucocyte pellets. Samples were only defrosted immediately before the performance of assays. Cerebrospinal fluid GCase assays were all performed within 7 and 14 days of sample collection. Leucocyte GCase assays were performed between 7 and 28 days of sample collection.

Details of the biochemical assays are provided in eMethods 3 and 4 in Supplement 2.

The statistical analyses followed a predefined statistical analysis plan written by the clinical trial statisticians (A.H.V.S. and J. Hosking). As the result of unforeseen circumstances, the statistician specified in the original protocol was not available to perform the final analysis. Therefore, a revised statistical analysis plan (eMethods 5 in Supplement 2) was produced before data analysis was conducted and the study was completed. All data analyses were performed using Stata software, version 14.2 (StataCorp LLC). The distribution of the outcomes was assessed through inspection of the plotted data (eFigures 1, 2, and 3 in Supplement 2). For the primary analysis, 95% CIs were presented alongside the results from a 2-sided t test (significance threshold of P < .05) of the change in CSF GCase activity. The lower CI and 1-sided t test results (significance threshold of P <.05) that were presented for the change in CSF ambroxol levels reflected the fact that the change was lower bounded by 0 because of anticipated 0 concentrations.
at baseline. To register as a change, ambroxol concentrations were required to be greater than the assay limit of detection of 0.5 ng/mL at 186 days. A descriptive analysis that correlated the change (Pearson coefficient) in ambroxol levels and the change in CSF GCase activity was also performed. The changes in secondary outcomes between baseline and 186 days were presented with 95% CIs. All data analyses were performed from November 1 to December 14, 2018.

**Results**

A total of 24 patients with moderate PD were evaluated for study eligibility. Of those, 23 patients entered the Ambroxol in the Modification of Parkinson Disease study. A total of 18 patients (15 men [83.3%]; mean [SD] age, 60.2 [9.7] years) completed the study. One participant withdrew at day 1 after treatment began, citing the high ambroxol tablet count (21 tablets per day), and 1 withdrew at 93 days after treatment began, citing family illness. Of the 18 patients who completed the study, I was excluded from the CSF analyses (including the primary analysis) because of a red blood cell contamination of more than 500 cells per cm³ in the baseline CSF sample (flow diagram of participant recruitment and retention in Figure 1).


Seven patients (3 with GBA1 mutations [GBA1⁺] and 4 without mutations [GBA1⁻]) underwent a third LP at 279 days. These 7 participants included the patient who was excluded from the analyses because of a blood-contaminated baseline CSF sample. As a result, 18 participants (8 GBA1⁺ and 10 GBA1⁻) were included in blood and clinical analyses at 186 and 279 days.

**Figure 1. Flow Diagram of Participant Recruitment and Retention**

<table>
<thead>
<tr>
<th>Patients prescreened</th>
<th>75</th>
</tr>
</thead>
<tbody>
<tr>
<td>Evaluated for eligibility</td>
<td>24</td>
</tr>
<tr>
<td>Underwent baseline LP (9 GBA1⁺ and 14 GBA1⁻)</td>
<td>23</td>
</tr>
<tr>
<td>Began ambroxol treatment (9 GBA1⁺ and 11 GBA1⁻)</td>
<td>20</td>
</tr>
<tr>
<td>Completed ambroxol treatment and underwent LP at 180 days (8 GBA1⁺ and 10 GBA1⁻)</td>
<td>18</td>
</tr>
<tr>
<td>Attended final study visit (8 GBA1⁺ and 10 GBA1⁻)</td>
<td>18</td>
</tr>
<tr>
<td>Included in final analyses (8 GBA1⁺ and 10 GBA1⁻)</td>
<td>18</td>
</tr>
<tr>
<td>Included in blood analyses at 180 and 270 days</td>
<td>18</td>
</tr>
<tr>
<td>Underwent optional final LP (3 GBA1⁺ and 4 GBA1⁻)</td>
<td>7</td>
</tr>
<tr>
<td>Included in CSF analysis at 270 days</td>
<td>6</td>
</tr>
<tr>
<td>Included in CSF analysis at 270 days</td>
<td>17</td>
</tr>
<tr>
<td>Excluded (GBA1⁻; CSF blood contamination of baseline sample)</td>
<td>18</td>
</tr>
<tr>
<td>Excluded (GBA1⁻; did not meet eligibility criteria)</td>
<td>1</td>
</tr>
<tr>
<td>Withdrew consent (2 GBA1⁻)</td>
<td>2</td>
</tr>
<tr>
<td>Withdrew consent (1 GBA1⁺ and 1 GBA1⁻)</td>
<td>2</td>
</tr>
<tr>
<td>Underwent final LP (3 GBA1⁺ and 4 GBA1⁻)</td>
<td>7</td>
</tr>
<tr>
<td>Included in CSF analysis at 270 days</td>
<td>6</td>
</tr>
<tr>
<td>Excluded (GBA1⁻; CSF blood contamination of baseline sample)</td>
<td>1</td>
</tr>
</tbody>
</table>

CSF indicates cerebrospinal fluid; GBA1⁻, negative glucocerebrosidase gene; GBA1⁺, positive glucocerebrosidase gene; and LP, lumbar puncture.
days. Seventeen participants (8 GBA1+ and 9 GBA1–) were included in the CSF analyses at 186 days, and 6 participants (3 GBA1+ and 3 GBA1–) were included in the CSF analyses at 279 days. Based on the number of empty ambroxol blister packs collected, we estimated a mean (SD) adherence to treatment of 89% (13%). Blood and CSF ambroxol levels at baseline confirmed that no participant had taken the drug before the treatment start date.

Table 2 shows a summary of results for participants who completed the study. The results of the GBA1+ and GBA1– subgroups are available in Tables 3 and 4 in Supplement 2.

### Primary and Secondary Outcomes

Ambroxol was undetectable in blood serum and CSF at baseline. At day 186, the CSF ambroxol level was 156 ng/mL (95% lower confidence limit, 129 ng/mL; 1-sided paired t test, \( P < .001 \)). At 186 days, the mean (SE) CSF ambroxol levels were 11% (6%) of the mean blood levels. As anticipated by our pre-trial CSF studies, which indicated inhibition of GCase in CSF rather than enhancement in tissues, the mean (SE) CSF GCase activity decreased by 0.059 (0.026) nmol/mL per hour (95% CI, -0.115 to -0.002; 2-sided paired t test, \( P = .04 \); Figure 2A), which was a 19% reduction from the mean baseline GCase activity.

The drug was well tolerated, and no serious AEs were reported. A total of 176 AEs occurred, of which 121 were deemed unrelated, 32 unlikely to be related, 15 possibly related, 5 probably related, and 3 definitely related to treatment. A full list of AEs is available in Table 5 and a list of recorded AEs is available in eTable 6 in Supplement 2. A mean (SD) weight loss of 1.3 (2.5) kg was observed between baseline and 186 days (95% CI, -2.59 to 0.01). No protocol deviations occurred.

Between baseline and 186 days, mean (SE) increases of 50 (17) pg/mL (13%) in total CSF α-synuclein concentration (95% CI, 14-87; \( P = .01 \); Figure 2B) and 88 (22) pmol/L (35%) in CSF GCase protein levels (95% CI, 40-137; \( P = .002 \); Figure 2C) were observed. Effect sizes did not indicate a significant change in CSF tau (mean [SE] change, 5 [8] pg/mL; 95% CI, -7 to 17; \( P = .36 \)) or glucosylceramide levels (mean [SE] change, 14 [9] pmol/L; 95% CI, -6 to 35; \( P = .16 \)). The correlation between ambroxol concentration and the change in CSF GCase activity was not significant (Pearson coefficient, \( r = -0.161 \); \( P = .52 \)). The CSF

### Table 2. Results of Participants Who Completed the Study

<table>
<thead>
<tr>
<th>Result*</th>
<th>Mean (SD)</th>
<th>Baseline</th>
<th>Day 11</th>
<th>Day 93</th>
<th>Day 186</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total participants, No.</td>
<td></td>
<td>18</td>
<td>18</td>
<td>18</td>
<td>18</td>
</tr>
<tr>
<td>Blood</td>
<td>17</td>
<td>17</td>
<td>17</td>
<td>17</td>
<td></td>
</tr>
<tr>
<td>CSF</td>
<td>17</td>
<td>17</td>
<td>17</td>
<td>17</td>
<td></td>
</tr>
<tr>
<td>Ambroxol, ng/mL</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blood serum</td>
<td>0</td>
<td>316 (196)</td>
<td>1084 (396)</td>
<td>1432 (570)*</td>
<td></td>
</tr>
<tr>
<td>CSF</td>
<td>0</td>
<td>NA</td>
<td>NA</td>
<td>156 (53)*</td>
<td></td>
</tr>
<tr>
<td>GCase activity</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blood leucocytes, nmol/mg/h</td>
<td>11.0 (5.2)</td>
<td>12.8 (4.9)</td>
<td>13.1 (4.8)</td>
<td>12.0 (5.2)</td>
<td></td>
</tr>
<tr>
<td>CSF, nmol/mL/h</td>
<td>0.309 (0.153)</td>
<td>NA</td>
<td>NA</td>
<td>0.250 (0.142)*</td>
<td></td>
</tr>
<tr>
<td>GCase protein level, pmol/L</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CSF</td>
<td>250 (47)</td>
<td>NA</td>
<td>NA</td>
<td>338 (104)*</td>
<td></td>
</tr>
<tr>
<td>α-Synuclein, pg/mL</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blood serum</td>
<td>20793 (9418)</td>
<td>19991 (7380)</td>
<td>24964 (9391)</td>
<td>23395 (9998)</td>
<td></td>
</tr>
<tr>
<td>CSF</td>
<td>383 (103)</td>
<td>NA</td>
<td>NA</td>
<td>433 (117)*</td>
<td></td>
</tr>
<tr>
<td>Tau, pg/mL</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blood serum</td>
<td>1.00 (0.25)</td>
<td>0.84 (0.24)</td>
<td>0.88 (0.22)</td>
<td>0.80 (0.24)*</td>
<td></td>
</tr>
<tr>
<td>CSF</td>
<td>206 (59)</td>
<td>NA</td>
<td>NA</td>
<td>211 (63)</td>
<td></td>
</tr>
<tr>
<td>Glucosylceramide, pmol/L</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CSF</td>
<td>246 (83)</td>
<td>NA</td>
<td>NA</td>
<td>260 (80)</td>
<td></td>
</tr>
<tr>
<td>MDS-UPDRS score</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Part 3</td>
<td>31.1 (14.5)</td>
<td>NA</td>
<td>27.2 (10.7)</td>
<td>24.3 (12.1)*</td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>62.6 (32.2)</td>
<td>NA</td>
<td>57.7 (27.6)</td>
<td>53.9 (30.3)*</td>
<td></td>
</tr>
<tr>
<td>MoCA score</td>
<td>25.0 (4.8)</td>
<td>NA</td>
<td>NA</td>
<td>26.7 (4.0)</td>
<td></td>
</tr>
<tr>
<td>NMS score</td>
<td>49.3 (36.1)</td>
<td>NA</td>
<td>NA</td>
<td>60.8 (38.6)*</td>
<td></td>
</tr>
<tr>
<td>NMSQuestion score</td>
<td>10.6 (6.0)</td>
<td>NA</td>
<td>NA</td>
<td>10.8 (6.0)</td>
<td></td>
</tr>
<tr>
<td>Weight, kg</td>
<td>83 (17)</td>
<td>83 (17)</td>
<td>82 (17)</td>
<td>82 (17)*</td>
<td></td>
</tr>
<tr>
<td>Arterial blood pressure, mm Hg</td>
<td>90 (8)</td>
<td>88 (9)</td>
<td>90 (10)</td>
<td>90 (11)</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: CSF, cerebrospinal fluid; GCase, glucocerebrosidase enzyme; MDS-UPDRS, Movement Disorders Society Unified Parkinson’s Disease Rating Scale; MoCA, Montreal Cognitive Assessment; NA, not applicable; NMSQuest, Non-Motor Symptoms Questionnaire; NMSS, Non-Motor Symptoms Scale.

* Clinical markers are recorded in the off state.

** Indicates a significant change from baseline to 186 days (analyzed by t test).
analysis of the 6 participants from whom CSF was collected at baseline, 186 days, and 279 days is presented in Table 4 in Supplement 2.

Between baseline and 186 days, mean (SE) blood leukocyte GCase activity increased by 1.0 (1.4) nmol/mg/h (95% CI, –2.0 to 4.0; P = .48) (Table 2 and Figure 2D). Wide variation was noted in the recorded change in serum α-synuclein concentration (mean [SE] change, 2602 [3649] pg/mL; 95% CI, –4689 to 9893; P = .46), although a mean (SE) decrease of 0.20 (0.08) pg/mL was observed in serum tau levels (95% CI, –0.37 to –0.05; P = .01).

Between baseline and 186 days, the mean (SD) total MDS-UPDRS score decreased (ie, improved) by 8.7 (11.8) points (95% CI, –15.3 to –2.2; P = .01) with a mean (SD) rebound of 7.2 (9.8) points between 186 and 279 days. This change appeared to be associated primarily with the MDS-UPDRS part 3 motor score (score range, 0-56, with 0 indicating no motor impairment and 56 indicating severe motor impairment), which showed a mean (SD) decrease of 6.8 (7.1) points between baseline and 186 days (95% CI, –10.4 to –3.1; P = .001) and a mean (SD) increase of 7.6 (7.0) points between 186 and 279 days. Seven of 18 patients increased their dopaminergic therapy during the course of the study, and the same deflection of MDS-UPDRS changes was observed in those on stable therapy and in those who increased their medication therapy (eFigures 4 and 5 in Supplement 2).

As anticipated, the change in MoCA scores were skewed and bound by 0 because of the preponderance of participants who maintained their scores from baseline. An increase (ie, improvement) in the mean (SD) MoCA scores of 1.7 (1.3) points was recorded between baseline and 186 days. In addition, the mean (SD) NMSS score increased (ie, worsened) by 11.5 (18.5) points (95% CI, –1.5 to 1.0; P = .72) between baseline and 186 days.

In Vitro Assays

Before the clinical trial, we performed in vitro assays to estimate the association of ambroxol, an inhibitory chaperone, with changes in GCase activity in acellular CSF. We added 500 nM (189 ng/mL), chosen on the basis of CSF ambroxol lev-
els reported in a previous clinical trial\(^7\) of ambroxol to human CSF taken from healthy participants (via diagnostic LPs for suspected idiopathic intracranial hypertension).

In addition, we performed a positive control by thermodynamically denaturing and chemically inhibiting GCase with conduritol B epoxide.\(^8\) The experiment comprised 5 technical repeats for CSF derived from 5 participants for each condition. Compared with the control samples, a mean (SD) decrease of 42% (12%) in CSF GCase activity (mean [SD] change in activity, -0.093 [0.026]; 95% CI, 0.046-0.140 nmol/mL per hour; \(P = .01\)) was observed after the addition of ambroxol. The denatured and conduritol B epoxide–inhibited samples registered no residual activity.

**Discussion**

To our knowledge, this study represents the first clinical trial of personalized therapy for a stratified (genetically defined) subtype of PD and the first use of ambroxol therapy in patients with PD. The study met its primary outcomes, which were to confirm that ambroxol was able to penetrate CSF and that it had a modulatory effect on CSF GCase. The finding that ambroxol penetrates CSF is consistent with a recent clinical trial of ambroxol (at an equivalent dose) in 5 patients with a mean age of 18 years who had neuronopathic Gaucher disease.\(^1\) Our study indicates that ambroxol therapy is well tolerated in patients with PD. This finding is important, as the administered dose was approximately 10 times higher and was administered for a longer duration than specified in its license.

Ambroxol has an inhibitory effect on GCase activity within acellular human CSF, which is consistent with its known activity as an inhibitory chaperone with a neutral pH. Within largely acellular CSF, the GCase protein is free, which is in contrast to its normal intracellular lysosomal location. Ambroxol is a pH–dependent inhibitory small molecular chaperone that binds to the active site of the GCase protein and reduces activity. Binding enables transportation to the lysosome and elution of free active enzymes under acidic conditions. Therefore, in acellular CSF, ambroxol will bind to and inhibit free GCase. However, in tissues, including those in the brain, ambroxol will increase intracellular GCase activity, as reported in studies of rodent and primate models.\(^7,8\)

The sustained upregulation of expression of CSF GCase protein levels indicates target engagement of ambroxol with the GCase pathway. The increase in total CSF α-synuclein concentration implies, based on previous in vitro and in vivo data,\(^6-9,11,15\) that ambroxol has also had an association with α-synuclein metabolism. These results suggest an increase in GCase activity within the brain itself, although this activity cannot, of course, be measured in vivo. No clear consensus exists on the association of PD with changes in total CSF α-synuclein, but reduced levels of total CSF α-synuclein have been described, while oligomeric and phosphorylated α-synuclein have increased.\(^3,10\) Ambroxol upregulates the expression of GCase, probably via the transcription factor EB pathway, and increases vesicular export.\(^9,21\) The increase in CSF α-synuclein could be interpreted as an increase of extracellular export of the protein from the brain parenchyma.

Interpretation of the changes in MDS-UPDRS and MoCA results is difficult in the context of a nonplacebo-controlled study. However, the changes support the clinical impression that no substantial deleterious effect of ambroxol was observed among participants taking ambroxol, including any adverse effect on the motor features of their PD.

**Limitations**

Our study has several limitations. The sample was relatively small, although the complexity of the study and its nature as a proof-of-concept clinical trial were factors in its design. A placebo arm was not used, so the clinical outcomes should be interpreted with caution. We could have elected to have a more genetically homogenous GBA1 study group, but this homogeneity may have limited the interpretation of the data. The mean age of our participants was 60.2 years, which is relatively young for patients with PD. However, this mean age was consistent with our inclusion criteria of a Hoehn and Yahr stage of 3 or less and was comparable with many drug intervention studies of patients with PD. Participants were recruited from databases of patients with PD with and without GBA1 mutations, but we do not believe this recruitment method resulted in a bias relevant to the biochemical biomarkers used as end points in this study.

**Conclusions**

In conclusion, we confirm that ambroxol has potential as a drug to target the glucocerebrosidase pathway in PD and increase GCase activity in the brain. These findings concur with cell and animal modeling, which indicate that ambroxol modulates α-synuclein levels. We believe ambroxol therapy has promise for further investigation as a drug to improve outcomes, particularly in patients who have PD with a GBA1 mutation and potentially in those without a GBA1 mutation. Larger placebo-controlled studies are warranted.
Ambroxol for Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations

Research  Original Investigation

Kingdom (Zetterberg); UK Dementia Research Institute at University College London London, United Kingdom (Zetterberg); Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Molndal, Sweden (Zetterberg); Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, Sahlgrenska Academy, University of Gothenburg, Molndal, Sweden (Zetterberg).

Author Contributions: Dr Mullin and Schapira had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Mullin, D’Souza, Woodgate, Efflein, Limousin, Libri, Schapira.

Acquisition, analysis, or interpretation of data: Mullin, Smith, Lee, Woodgate, Efflein, Hallquist, Toffoli, Streeter, Hosking, Heywood, Khengar, Campbell, Heir, Mills, Zetterberg, Libri, Foltynie, Schapira.

Drafting of the manuscript: Mullin, Smith, D’Souza, Hallquist, Streeter, Khengar, Campbell, Mills, Zetterberg, Libri, Foltynie, Schapira.

Critical revision of the manuscript for important intellectual content: Mullin, Smith, Lee, Woodgate, Efflein, Toffoli, Streeter, Hosking, Heywood, Campbell, Heir, Mills, Zetterberg, Limousin, Libri, Foltynie.

Statistical analysis: Mullin, Streeter, Hosking. Obtained funding: Mullin, Libri, Schapira.

Administrative, technical, or material support: Mullin, Lee, D’Souza, Woodgate, Efflein, Hallquist, Toffoli, Heywood, Khengar, Heir, Cable, Mills, Zetterberg.

Supervision: Efflein, Limousin, Schapira.

Conflict of Interest Disclosures: Dr Foltynie reported having received honoraria for speaking at meetings supported by Profile Pharma, BIAL, AbbVie; having served on advisory boards for BiAL, Oxford Biomedica, Living Cell Technologies, and Peptron. Dr Zetterberg reported having served at scientific advisory boards for Roche Diagnostics, Wave, Samumed, and CoqRx; having given lectures in symposia sponsored by Alzecure and Biogen; and reported being a co-founder of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures-based platform company at the University of Gothenburg. Dr Limousin reported having received travel support and honoraria from Boston Scientific and Medtronon. Dr Heywood reported having received funding and travel support from Shire Pharmaceuticals; and reported having received honoraria from Freeline Therapeutics. Dr Mills reported having received honoraria from Freeline Therapeutics; and having received travel support from Actelion and Genzyme Sanofi. Dr Libri reported having served on Advisory Boards for Biogen and Nova Laboratories Ltd. Dr Streeter reported being a consultant to Sanofi, Prevail, Infalzone, and Kyowa. No other disclosures were reported.

Funding/Support: This research was funded by grant 555854 from the Cure Parkinson’s Disease Trust, grants MRF/LSI/4959/1 and MR/M006646/1 from the Medical Research Council (Dr Toffoli), grant 2018-02532 from the Swedish Research Council (Dr Zetterberg), grant 681712 from the European Research Council (Dr Zetterberg), and grant ALFGGB-720931 from Swedish State Support for Clinical Research (Dr Zetterberg). This research was also supported by the National Institute for Health Research University College London Hospitals Biomedical Research Centre, the Leonard Wolfson Experimental Neurology Centre, the Great Ormond Street Hospital Biomedical Research Centre (Dr Zetterberg), and the UK Dementia Research Institute (Dr Zetterberg).

Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

REFERENCES


